India, Sept. 23 -- Glenmark Pharmaceuticals said on Wednesday that it has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its formulations manufacturing facility in Goa.
The inspection was concluded with a Voluntary Action Indicated (VAI) classification, the company said in a regulatory filing.
Under the US FDA's classification, a VAI status indicates that objectionable conditions were identified, but the regulator does not recommend regulatory action. The company is expected to address the observations through voluntary corrective measures.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....